A real-world study of wearable sensors in Parkinson’s disease

被引:0
作者
Jamie L. Adams
Karthik Dinesh
Christopher W. Snyder
Mulin Xiong
Christopher G. Tarolli
Saloni Sharma
E. Ray Dorsey
Gaurav Sharma
机构
[1] University of Rochester Medical Center,Department of Neurology
[2] University of Rochester Medical Center,Center for Health + Technology
[3] University of Rochester,Department of Electrical and Computer Engineering
[4] Rochester General Hospital,undefined
[5] Microbiology,undefined
[6] Michigan State University College of Human Medicine,undefined
来源
npj Parkinson's Disease | / 7卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Most wearable sensor studies in Parkinson’s disease have been conducted in the clinic and thus may not be a true representation of everyday symptoms and symptom variation. Our goal was to measure activity, gait, and tremor using wearable sensors inside and outside the clinic. In this observational study, we assessed motor features using wearable sensors developed by MC10, Inc. Participants wore five sensors, one on each limb and on the trunk, during an in-person clinic visit and for two days thereafter. Using the accelerometer data from the sensors, activity states (lying, sitting, standing, walking) were determined and steps per day were also computed by aggregating over 2 s walking intervals. For non-walking periods, tremor durations were identified that had a characteristic frequency between 3 and 10 Hz. We analyzed data from 17 individuals with Parkinson’s disease and 17 age-matched controls over an average 45.4 h of sensor wear. Individuals with Parkinson’s walked significantly less (median [inter-quartile range]: 4980 [2835–7163] steps/day) than controls (7367 [5106–8928] steps/day; P = 0.04). Tremor was present for 1.6 [0.4–5.9] hours (median [range]) per day in most-affected hands (MDS-UPDRS 3.17a or 3.17b = 1–4) of individuals with Parkinson’s, which was significantly higher than the 0.5 [0.3–2.3] hours per day in less-affected hands (MDS-UPDRS 3.17a or 3.17b = 0). These results, which require replication in larger cohorts, advance our understanding of the manifestations of Parkinson’s in real-world settings.
引用
收藏
相关论文
共 81 条
[1]  
Collaborators GPD(2018)Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 Lancet Neurol. 17 939-953
[2]  
Marras C(2002)Predicting motor decline and disability in Parkinson disease: a systematic review Arch. Neurol. 59 1724-1728
[3]  
Rochon P(2004)The rate of cognitive decline in Parkinson disease Arch. Neurol. 61 1906-1911
[4]  
Lang AE(2011)Impact of psychiatric symptoms and sleep disorders on the quality of life of patients with Parkinson’s disease J. Neurol. 258 494-499
[5]  
Aarsland D(2018)Teleneurology and mobile technologies: the future of neurological care Nat. Rev. Neurol. 14 285-297
[6]  
Gomez-Esteban JC(2020)Direct cost of Parkinson’s Disease: a real-world data study of second-line therapies Parkinsons Dis. 2020 9106026-63
[7]  
Dorsey ER(2017)Inventory of real world data sources in Parkinson’s disease BMC Neurol. 17 52-1752
[8]  
Glidden AM(2017)Multiple wearable sensors in Parkinson and Huntington disease individuals: a pilot study in clinic and at home Digit Biomark. 1 1740-1637
[9]  
Holloway MR(2018)Wearable sensors for clinical applications in epilepsy, Parkinson’s disease, and stroke: a mixed-methods systematic review J. Neurol. 265 1628-394
[10]  
Birbeck GL(2013)Quantitative wearable sensors for objective assessment of Parkinson’s disease Mov. Disord. 28 e0183989-45